Abstract Number: 1789 • 2015 ACR/ARHP Annual Meeting
Infections Observed in Rituximab Treated Patients with Refractory Systemic Lupus Erythematosus (SLE): Results from a National Multicentre Register
Background/Purpose: SLE is associated with a significantly increased risk of infection. Both disease activity and the medications required to control disease are contributory factors. Rituximab…Abstract Number: 1790 • 2015 ACR/ARHP Annual Meeting
Mycophenolate Mofetil Suppresses Humoral Response to Pneumococcal Vaccine in Patients with Systemic Lupus Erythematosus and Other Autoimmune Diseases
Background/Purpose: To determine the efficacy of pneumococcal polysaccharide vaccine (PPV-23) in patients on mycophenolate mofetil (MMF) therapy and compare efficacy to other DMARDS.Methods: In…Abstract Number: 1791 • 2015 ACR/ARHP Annual Meeting
Does Renin-Angiotensin System Blockade Protect Lupus Nephritis Patients from Atherosclerotic Cardiovascular Events? a Case-Control Study
Background/Purpose: Angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are currently used as an adjuvant treatment in lupus nephritis (LN) patients for the…Abstract Number: 1792 • 2015 ACR/ARHP Annual Meeting
Optimal Monitoring for Coronary Heart Disease Risk in Systemic Lupus Erythematosus Patients: a Systematic Review
Background/Purpose: Premature coronary heart disease (CHD) represents a significant cause of morbidity and mortality in systemic lupus erythematosus (SLE). Several studies have been conducted to…Abstract Number: 1793 • 2015 ACR/ARHP Annual Meeting
Is There a Relationship Between Antimalarial Treatment and Elevated Muscle Enzymes in Systemic Lupus Erythematosus
Background/Purpose: Elevated muscle enzymes in the course of systemic lupus erythematosus (SLE) usually represent active myositis or drug-related toxicity. Lipid-lowering agents and, less frequently, antimalarials…Abstract Number: 1794 • 2015 ACR/ARHP Annual Meeting
Unexplained Decline in Rates of Cardiovascular Events in a Large Cohort of SLE Patients
Background/Purpose: We have observed a decline in rates of cardiovascular events in systemic lupus erythamatosus (SLE) pateints in our clinic. In this work presented below,…Abstract Number: 1795 • 2015 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy of Tacrolimus for Lupus Nephritis Patients in Real World Setting -Results from 5 Year Interim Analysis of Post Marketing Surveillance of 1376 Patients in Japan-
Background/Purpose: Tacrolimus (Tac) is an immunosuppressive macrolide that blocks T cell activation by specifically inhibiting calcineurin. Some randomized controlled studies have shown that TAC is an…Abstract Number: 1796 • 2015 ACR/ARHP Annual Meeting
Progression of Atherosclerosis Might be Prevented By Decrease of Serum Resistin Level after Glucocorticoid Therapy in Patients with Systemic Autoimmune Disease
Background/Purpose: Development of atherosclerosis is accelerated in patients with systemic autoimmune diseases. However, underlying mechanisms of accelerated atherosclerosis remains unknown, and the impact of pharmacotherapies…Abstract Number: 1797 • 2015 ACR/ARHP Annual Meeting
Insulin Resistance Is Not Associated with Increased Risk of Subclinical Atheromatosis in Patients with Systemic Lupus Erythematosus from Northern Spain
Background/Purpose: Metabolic syndrome is a recently defined clustering of cardiovascular risk (CV) factors associated with insulin resistance (IR) and an increased risk of CV disease.…Abstract Number: 1798 • 2015 ACR/ARHP Annual Meeting
Progression of Noncalcified and Calcified Coronary Plaque (by CT Angiography) in SLE
Background/Purpose: Accelerated atherosclerosis leading to premature coronary artery disease remains the major cause of late death in SLE. Coronary artery calcium (CAC) is a late…Abstract Number: 1799 • 2015 ACR/ARHP Annual Meeting
IgG Levels Correlate Inversely with Proteinuria Among Participants in the Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis Trial, but Hypogammaglobulinemia Was Not Associated with an Increased Risk of Serious Infection
Background/Purpose: Hypogammaglobulinemia has been associated with serious infectious adverse events (SIAE) and may occur during immunosuppressive therapy for lupus nephritis (LN). It is possible that…Abstract Number: 1800 • 2015 ACR/ARHP Annual Meeting
A Novel Anti-CD28 Domain Antibody Antagonist Shows a Favorable Pharmacokinetic, Pharmacodynamic and Safety Profile
Background/Purpose: Antagonism of the CD28 costimulation receptor is thought to block T-cell activation, making this a promising target for the treatment of many autoimmune diseases,…Abstract Number: 1801 • 2015 ACR/ARHP Annual Meeting
Hydroxychloroquine Retinopathy: Application of the 2011 Screening Guidelines in an Academic Practice
Background/Purpose: The risk of end-stage retinopathy (bull’s eye maculopathy) from hydroxychloroquine (HCQ) is low (0.65%, Wolfe and Marmor, 2010). With recent advances in retinal structure…Abstract Number: 1802 • 2015 ACR/ARHP Annual Meeting
Hydroxychloroquine Level Variants and Predictors in a Connective Tissue Disease Population
Background/Purpose: Hydroxychloroquine (HCQ) dose adjustment in patients with impaired renal function has been suggested to prevent toxicity. However, evidence to support this practice is scant. …Abstract Number: 1803 • 2015 ACR/ARHP Annual Meeting
Serum Adipocyte Fatty Acid-Binding Protein Level Is Elevated in Patients with Systemic Lupus Erythematosus (SLE) but Not Associated with Biophysical Markers of Cardiovascular Disease
Background/Purpose: Adipocyte fatty acid-binding protein (aFABP) is an intracellular lipid-binding protein expressed in adipocytes and macrophages, particularly in inflammatory conditions. Recently, high circulating serum aFABP…
ACR Meeting Abstracts